Spero Therapeutics Inc (SPRO) Unusual Options Activity Today

Checking SPRO unusual options activity helps you spot when traders are making outsized bets on Spero Therapeutics Inc before the broader market catches on. Spero Therapeutics Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor SPRO unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching SPRO unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking SPRO unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and SPRO unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease.

It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Catalysts rarely arrive without a footprint, and SPRO unusual options activity is often where that footprint shows up first. Our scanner tracks Spero Therapeutics Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at SPRO unusual options volume on the call side or chasing put sweeps, Spero Therapeutics Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.